These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449 [TBL] [Abstract][Full Text] [Related]
30. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods. Smith TRF; Schultheis K; Broderick KE Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156 [TBL] [Abstract][Full Text] [Related]
31. Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Ivanov V; Oomens AGP; Papin JF; Staats R; Reuter DN; Yu Z; Piedra PA; Wellliver RC Vaccine; 2021 Jul; 39(30):4063-4071. PubMed ID: 34140172 [TBL] [Abstract][Full Text] [Related]
32. Adjustable Algorithmic Tool for Assessing the Effectiveness of Maternal Respiratory Syncytial Virus (RSV) Vaccination on Infant Mortality in Developing Countries. Cevigney R; Leary C; Gonik B Infect Dis Obstet Gynecol; 2021; 2021():5536633. PubMed ID: 34121834 [TBL] [Abstract][Full Text] [Related]
33. Lessons learned from COVID-19 vaccine acceptance among pregnant and lactating women from two districts in Kenya to inform demand generation efforts for future maternal RSV vaccines. Limaye RJ; Singh P; Fesshaye B; Karron RA BMC Pregnancy Childbirth; 2024 Mar; 24(1):221. PubMed ID: 38539077 [TBL] [Abstract][Full Text] [Related]
35. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants. Srikantiah P; Klugman KP BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242 [TBL] [Abstract][Full Text] [Related]
36. The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis. Zhu T; Zhang C; Yu L; Chen J; Qiu H; Lyu W; Huang S Virol Sin; 2015 Oct; 30(5):371-8. PubMed ID: 26511990 [TBL] [Abstract][Full Text] [Related]
37. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine. Blunck BN; Rezende W; Piedra PA Expert Rev Vaccines; 2021 Apr; 20(4):351-364. PubMed ID: 33733995 [TBL] [Abstract][Full Text] [Related]
38. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies. Srikantiah P; Vora P; Klugman KP Clin Infect Dis; 2021 Sep; 73(Suppl_3):S177-S179. PubMed ID: 34472571 [TBL] [Abstract][Full Text] [Related]
39. Immunopathology of RSV infection: prospects for developing vaccines without this complication. van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293 [TBL] [Abstract][Full Text] [Related]
40. Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Kaaijk P; Luytjes W; Rots NY Hum Vaccin Immunother; 2013 Jun; 9(6):1263-7. PubMed ID: 23442726 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]